Overview
Ibogaine is a psychoactive indole alkaloid derived from Tabernanthe iboga and is investigated mainly for substance use disorders, especially opioid use disorder.[1] In the context of ibogaine treatment, a reported “success rate” may refer to acute withdrawal suppression, reduced craving, completion of detoxification, short-term abstinence, long-term abstinence, or broader improvements in functioning.[2][3]
The most defensible summary is that ibogaine may help many patients through the first days of opioid withdrawal, but it has not been proven to produce consistent long-term recovery as a stand-alone intervention.[1][2] Claims of very high “cure rates” should be interpreted cautiously because much of the evidence comes from uncontrolled cohorts, surveys, retrospective reports, or clinic marketing rather than randomized controlled trials.[4][5]
Reported Success Rates by Outcome
Published observational research suggests that short-term opioid withdrawal relief is more consistently reported than long-term abstinence.[1][2] In the Brown and Alper 12-month follow-up study of people treated at a clinic in Mexico, self-reported opioid abstinence was approximately 50% at 1 month, 33% at 3 months, 20% at 6 months, 17% at 9 months, and 13% at 12 months.[2]
- Acute opioid withdrawal reduction: often described as substantial in observational clinical reports and surveys, but not confirmed by large blinded placebo-controlled trials.[1][4]
- One-month abstinence: about half of participants in one small Mexico cohort reported no opioid use in the previous 30 days.[2]
- Three- to six-month abstinence: rates generally declined over time in the same cohort, which is consistent with ibogaine functioning more as a detoxification window than as a complete recovery program.[2][3]
- Twelve-month abstinence: durable abstinence appears possible for some patients, but published estimates are highly uncertain because samples are small and follow-up is incomplete.[2][3]
Human Clinical Evidence
The Brown and Alper study is one of the most frequently cited opioid-use outcome papers because it followed 30 people with opioid use disorder for up to 12 months after ibogaine treatment in Mexico.[2] The study found rapid reductions in withdrawal symptoms and a marked short-term decline in opioid use, but it relied primarily on self-report and had no randomized comparison group.[2]
The New Zealand observational study by Noller, Frampton, and Yazar-Klosinski also followed a small group of opioid-dependent participants for 12 months and reported reductions in opioid use and addiction severity measures after ibogaine treatment.[3] Because the sample was small and treatment was not randomized, the study supports further research but does not establish a precise population-level success rate.[3]
Mash and colleagues reported clinical observations from a medically monitored ibogaine detoxification program involving people with opioid and cocaine dependence.[1] That work supports the idea that ibogaine may reduce withdrawal, craving, and depressive symptoms during transition from dependence to abstinence, but the open-label design prevents firm causal conclusions.[1]
Survey research by Davis and colleagues found that many respondents reported subjective reductions in opioid withdrawal and craving after ibogaine, but the authors emphasized that online self-selected samples are vulnerable to recall bias, expectancy bias, and survivorship bias.[4] Retrospective research from Brazil by Schenberg and colleagues reported longer post-treatment abstinence intervals among people treated for mixed substance dependence, particularly when ibogaine was paired with psychotherapy, but the study did not provide controlled opioid-specific efficacy data.[6]
Why Success Rates Vary
Ibogaine success rates vary because studies use different definitions of success and because patients differ in opioid type, fentanyl exposure, methadone history, psychiatric comorbidity, medical risk, treatment setting, and aftercare participation.[2][3] A person who completes detoxification without withdrawal is a different outcome category from a person who remains abstinent for 12 months with verified toxicology testing.[2]
Follow-up loss can also distort reported success rates because people who relapse may be less likely to respond to researchers or clinics.[4] Conversely, counting all lost participants as relapsed may understate benefit for some individuals, which is why controlled trials with predefined endpoints are needed.[3]
Commercial and clinic-facing websites sometimes report broad success ranges such as 50–80% or highlight high rates of symptom improvement, but those figures are usually not equivalent to independently verified long-term abstinence.[5][7][8][9] Such reports may be useful for understanding how treatment is marketed, but they should be separated from peer-reviewed evidence when estimating true treatment effectiveness.[4][5]
Mechanisms That May Contribute to Outcomes
Ibogaine is metabolized into noribogaine, an active metabolite believed to contribute to prolonged anti-withdrawal and anti-craving effects.[1] Proposed mechanisms include modulation of opioid signaling, effects on serotonin transport, NMDA receptor activity, and changes in reward circuitry, although the relative contribution of each pathway in humans remains uncertain.[1][4]
The subjective psychedelic experience may also influence motivation, autobiographical reflection, and psychological insight, but those effects have not been cleanly separated from pharmacological withdrawal suppression in controlled addiction trials.[4] For readers interested in the broader experience and clinical model, see Ibogaine Trip: Effects, Risks, Evidence and Ibogaine Therapy: Evidence, Risks & Legality.[1]
Safety Risks and Their Effect on Treatment Success
Ibogaine has a higher acute medical risk profile than most approved addiction medications, especially because it can prolong cardiac repolarization and the QT interval.[10][11] Published forensic reviews have identified deaths temporally associated with ibogaine ingestion, often involving cardiac disease, polysubstance use, electrolyte abnormalities, or inadequate screening.[10]
Cardiac mechanisms of concern include hERG potassium-channel blockade, QT prolongation, torsades de pointes risk, bradycardia, and potentially fatal arrhythmias.[11] These risks mean that a “successful” ibogaine treatment must include not only withdrawal relief or abstinence but also safe medical screening, continuous monitoring, and emergency readiness.[10][11]
People considering treatment should review Ibogaine Side Effects: Risks & Safety, Ibogaine Treatment Centers: Safety, Legality & Choosing One, and How to Get Ibogaine Treatment Safely before interpreting success-rate claims.[10][11]
Comparison With Standard Opioid Use Disorder Treatments
Ibogaine is sometimes compared with buprenorphine, methadone, or extended-release naltrexone, but direct comparison is difficult because ibogaine studies are generally small and uncontrolled while standard medications have been evaluated in larger clinical and epidemiological research programs.[2][12]
Methadone and buprenorphine maintenance are associated with reduced all-cause and overdose mortality during treatment, which is a major evidence-based advantage over detoxification-only approaches.[12] Extended-release naltrexone can be effective after successful induction, but initiation is harder because patients must first complete detoxification.[13]
Ibogaine may create a rapid detoxification window for some patients, but it has not shown the same level of mortality-reduction evidence as methadone or buprenorphine.[2][12]
Legal Status and Access
In the United States, ibogaine is listed as a Schedule I controlled substance, which means it cannot be legally administered as a routine clinical treatment outside authorized research.[14] This legal status has contributed to medical tourism to countries such as Mexico, where clinic standards vary widely.[5][8]
Access rules differ by country, and New Zealand has been notable for allowing prescription-based use under limited conditions that enabled observational follow-up research.[3] Readers comparing jurisdictions can consult Ibogaine Legality by Country, Ibogaine Treatment in Mexico, and Ibogaine Treatment in the United States.[14]
Emerging Research and Future Outlook
Recent interest in ibogaine has expanded beyond addiction into traumatic brain injury, PTSD symptoms, depression, anxiety, and functional disability.[15] A Stanford-associated 2024 Nature Medicine study reported improvements among U.S. Special Operations Forces veterans treated outside the United States with a protocol involving ibogaine, magnesium, and 5-MeO-DMT, but the study was not a randomized addiction-treatment trial.[15]
Policy interest has also increased, including a Washington State budget proposal to fund research into ibogaine treatment for opioid use disorder.[16] Future research needs include randomized controlled trials, standardized dosing, cardiac risk stratification, verified toxicology outcomes, fentanyl-specific protocols, and structured aftercare models.[2][10]
Until such research is available, ibogaine should be described as a promising but medically risky investigational intervention rather than a proven cure for addiction.[1][11] For related topics, see Ibogaine for PTSD and Ibogaine for TBI.[15]